Cullinan's Zipalertinib Plus Chemotherapy Hits Primary Endpoint in Phase 3 REZILIENT3, Interim Data Headed to WCLC Presidential Symposium
核心洞察
Cullinan Therapeutics' Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy met its primary progression-free survival endpoint at a planned interim analysis in first-line EGFR exon 20 insertion NSCLC.
Interim results will be presented in Presidential Symposium 2 at the IASLC 2026 World Conference on Lung Cancer on September 13, 2026, in Seoul, South Korea.
Cullinan will host a virtual analyst and investor event on September 14, 2026, at 8:00 a.m. ET, featuring CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones, MD, MBA.
Cullinan Therapeutics announced that the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (搜索) (EGFR) exon 20 insertion mutation-positive non-small cell lung cancer (搜索) (NSCLC) met its primary endpoint of progression-free survival at a planned interim analysis. The Cambridge, Massachusetts-based company disclosed the results ahead of a Presidential Symposium presentation scheduled for the IASLC 2026 World Conference on Lung Cancer.
Interim Data Slated for Presidential Symposium 2
Results from the planned interim analysis will be presented in Presidential Symposium 2 on Sunday, September 13, 2026, at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC). The conference is being held September 12-15, 2026, in Seoul, South Korea.
The Presidential Symposium designation places the REZILIENT3 interim analysis among the meeting's highest-profile data presentations, reflecting the clinical relevance of the EGFR exon 20 insertion mutation (搜索)-positive NSCLC population, a subset of lung cancer historically associated with limited benefit from established EGFR-targeted therapies.
Investor Event to Follow Presentation
Cullinan Therapeutics will host a virtual event for analysts and institutional investors on Monday, September 14, 2026, at 8:00 a.m. ET, following the Presidential Symposium presentation. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer.
A live webcast will be available via the events page of Cullinan Therapeutics' investor relations website, with a replay archived on the website following the event.
Trial Design and Endpoint
REZILIENT3 is a Phase 3 trial evaluating zipalertinib in combination with chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation (搜索)-positive NSCLC. The trial's primary endpoint is progression-free survival, which was met at the planned interim analysis, according to the company's previously announced results.
The announcement did not disclose the magnitude of the progression-free survival benefit, the number of patients enrolled, or additional efficacy and safety data; those details are expected to accompany the Presidential Symposium presentation.
Company Pipeline Context
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) describes itself as a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer. The company states that it pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. Cullinan characterizes its pipeline as clinical-stage and built on a rigorous scientific approach and purposeful innovation, with a stated mission to deliver new standards of care for patients.